

IN THE CLAIMS

Please delete all prior lists of claims in the application and insert the following list of claims.

1. (CURRENTLY AMENDED) A selective growth medium specific for *Listeria spp.* comprising, in combination, lithium chloride and one or more antibiotics or salts thereof[[,]] in concentrations effective to selectively inhibit non-*Listeria* organisms while enhancing growth of *Listeria spp.*, **wherein the one or more antibiotics comprises nitrofurantoin.**
2. (CURRENTLY AMENDED) The medium of claim 1, wherein the **one or more** antibiotics **further comprise an antibiotic** ~~are~~ selected from the group consisting of **ceftazidime** ~~ceftazimide~~, phosphomycin, **and** polymyxin, ~~and nitrofurantoin.~~
3. (ORIGINAL) The medium of claim 1, being substantially devoid of acriflavin.
4. (ORIGINAL) The medium of claim 1, further comprising esculin.
5. (ORIGINAL) The medium of claim 1, wherein the lithium chloride is present in a concentration of from about 1 g/L to about 10 g/L.
6. (CURRENTLY AMENDED) The medium of claim 5, wherein the lithium chloride is present in a concentration of from about **1 g/L to about** 5 g/L.
7. (CURRENTLY AMENDED) The medium of claim **1** ~~2~~, wherein the nitrofurantoin is present in a concentration of from about .001 g/L to about 0.01 g/L.
8. (ORIGINAL) The medium of claim 7, wherein the nitrofurantoin is present in a concentration of about .006 g/L.

9. (CURRENTLY AMENDED) A selective and differential medium for *Listeria spp.* comprising an agar base layer substantially devoid of acriflavin, the base layer containing lithium chloride, **cycloheximide**, a growth enhancer of *Listeria spp.*, and antibiotics or salts thereof in concentrations effective to **enhance growth of *Listeria spp.* and** selectively inhibit non-*Listeria* organisms.
10. (ORIGINAL) The medium of claim 9, wherein the growth enhancer comprises an iron-containing compound.
11. (ORIGINAL) The medium of claim 10, wherein the growth enhancer is ferric ammonium citrate.
12. (CURRENTLY AMENDED) The medium of claim 9, wherein the antibiotics are selected from the group consisting of **ceftazidime** ~~ceftazimide~~, phosphomycin, polymyxin, and nitrofurantoin.
13. (ORIGINAL) The medium of claim 12, wherein the polymyxin is polymyxin E.
14. (CANCELED)
15. (CURRENTLY AMENDED) ~~The medium of claim 14, further comprising, in combination, ceftazimide~~ **A *Listeria spp.*-selective medium comprising, in combination, cycloheximide, naladixic acid, ferric ammonium citrate, esculin, ceftazidime,** phosphomycin, polymyxin E, lithium chloride, and nitrofurantoin in concentrations effective **to promote growth of *Listeria spp.* and** to inhibit growth of non-*Listeria* organisms.
16. (CURRENTLY AMENDED) The medium of claim ~~15~~ **14**, the medium being substantially devoid of acriflavin.
17. (CURRENTLY AMENDED) The medium of claim ~~14~~, ~~wherein the~~ **15, further comprising** tryptone **in a** concentration **of is** about 17.0 g/L.

18. (CURRENTLY AMENDED) The medium of claim ~~14~~, ~~wherein the~~ 15, further comprising peptone in a concentration of is about 3.0 g/L.

19. (CURRENTLY AMENDED) The medium of claim ~~14~~, ~~wherein the~~ 15, further comprising sodium chloride in a concentration of is about 5.0 g/L.

20. (CURRENTLY AMENDED) The medium of claim ~~14~~, ~~wherein the~~ 15, further comprising dibasic potassium phosphate in a concentration of is about 6.0 g/L.

21. (CURRENTLY AMENDED) The medium of claim ~~14~~, ~~wherein the~~ 15, further comprising yeast extract in a concentration of is about 6.0 g/L.

22. (CURRENTLY AMENDED) The medium of claim 15 ~~14~~, wherein the cycloheximide ~~cyclohexamide~~ concentration is about 0.05 g/L.

23. (CURRENTLY AMENDED) The medium of claim 15 ~~14~~, wherein the naladixic acid concentration is about 0.04 g/L.

24. (CURRENTLY AMENDED) The medium of claim 15 ~~14~~, wherein the esculin concentration is about 1.0 g/L.

25. (CURRENTLY AMENDED) The medium of claim 15, wherein the ceftazidime ~~ceftazimide~~ concentration is about 0.04 g/L.

26. (ORIGINAL) The medium of claim 15, wherein the phosphomycin concentration is about 0.04 g/L.

27. (ORIGINAL) The medium of claim 15, wherein the polymyxin E concentration is about 0.01 g/L.
28. (CURRENTLY AMENDED) The medium of claim ~~15~~ **14**, wherein the ferric ammonium citrate concentration is about 0.5 g/L.
29. (ORIGINAL) The medium of claim 15, wherein the lithium chloride concentration is about 5.0 g/L.
30. (ORIGINAL) The medium of claim 15, wherein the nitrofurantoin concentration is about .006 g/L.
31. (CURRENTLY AMENDED) A *Listeria spp.*-selective medium comprising, in combination,
- tryptone, in a concentration of about 17.0 g/L;
 - peptone, in a concentration of about 3.0 g/L;
 - sodium chloride, in a concentration of about 5.0 g/L,
 - anhydrous dibasic potassium phosphate, in a concentration of about 6.0 g/L;
 - yeast extract, in a concentration of about 6.0 g/L;
 - ~~cycloheximide~~ **cyclohexamide**, in a concentration of about 0.05 g/L;
 - naladixic acid, in a concentration of about 0.04 g/L;
 - esculin, in a concentration of about 1.0 g/L;
 - ~~ceftazimide~~ **ceftazidime**, in a concentration of about 0.04 g/L;
 - phosphomycin, in a concentration of about 0.04 g/L;
 - polymyxin E, in a concentration of about 0.01 g/L;
 - ferric ammonium citrate, in a concentration of about 0.5 g/L;
 - lithium chloride, in a concentration of about 5.0 g/L; and
 - nitrofurantoin, in a concentration of about 0.006 g/L.

32. (NEW) The medium of Claim 1, wherein the medium further comprises cycloheximide and is substantially devoid of acriflavin.

33. (NEW) The medium of Claim 15, wherein the medium is substantially devoid of acriflavin.

34. (NEW) The medium of Claim 31, wherein the medium is substantially devoid of acriflavin.